On Apr. 8, 2020, PharmaCyte Biotech announced a license agreement with Hai Kang Life Corp. whereby PharmaCyte received license to certain technology owned or controlled by Hai Kang related to COVID-19 diagnostic kits. PharmaCyte may directly (or through a third party) conduct research, use, develop, market, sell, distribute, import and export Products for human and veterinary uses in North America, the UK and certain other European cites.